Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis

International Immunology

Volumn 27, Issue 1, 2015, Pages 47-53

  Schwab, Nicholas ^a   Schneider Hohendorf, Tilman ^a   Wiendl, Heinz ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Natalizumab; Progressive multifocal leukoencephalopathy; Risk stratification

Indexed keywords

L SELECTIN; NATALIZUMAB; VERY LATE ACTIVATION ANTIGEN 4; MONOCLONAL ANTIBODY;

ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CELL ADHESION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; TREATMENT DURATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; IMMUNOLOGY; IMMUNOTHERAPY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; METABOLISM; PROCEDURES; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD-BRAIN BARRIER; HUMANS; IMMUNOTHERAPY; INTEGRIN ALPHA4BETA1; L-SELECTIN; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; RISK FACTORS; VIRUS DISEASES;

EID: 84922423174     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxu096     Document Type: Article

References (75)

1. Hooks, M. A., Wade, C. S. and Millikan, W. J. Jr. 1991. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11:26.
2. Saghafi, H., Rahbar, K., Nobakht Haghighi, A., Qoreishi, M. and Safdari, F. 2012. Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation. Nephrourol. Mon. 4:475.
3. Dubertret, L., Sterry, W., Bos, J. D., et al. 2006. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br. J. Dermatol. 155:170.
4. Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L. and Karin, N. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63.
5. Polman, C. H., Reingold, S. C., Banwell, B., et al. 2011. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69:292.
6. Stüve, O. and Wiendl, H. 2009. Iatrogenic immunosuppression with biologics in MS: expecting the unexpected? Neurology 73:1346.
7. Steinman, L. 2014. Immunology of relapse and remission in multiple sclerosis. Annu. Rev. Immunol. 32:257.
8. Bloomgren, G., Richman, S., Hotermans, C., et al. 2012. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366:1870.
9. Schwab, N., Hohn, K. G., Schneider-Hohendorf, T., et al. 2012. Immunological and clinical consequences of treating a patient with natalizumab. Mult. Scler. 18:335.
10. Schwab, N., Ulzheimer, J. C., Fox, R. J., et al. 2012. Fatal PML associated with efalizumab therapy: insights into integrin αLß2 in JC virus control. Neurology 78:458.
11. Sospedra, M. and Martin, R. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683.
12. Hession, R. M., Sharma, V., Spiegel, D. E., et al. 2013. Multiple sclerosis disease progression and paradichlorobenzene: a tale of mothballs and toilet cleaner. JAMA Neurol. 71:228.
13. Meuth, S. G., Göbel, K. and Wiendl, H. 2012. Immune therapy of multiple sclerosis-future strategies. Curr. Pharm. Des. 18:4489.
14. Herrero-Herranz, E., Pardo, L. A., Gold, R. and Linker, R. A. 2008. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol. Dis. 30:162.
15. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer, S., et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214.
16. Flügel, A., Berkowicz, T., Ritter, T., et al. 2001. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14:547.
17. Serafini, B., Rosicarelli, B., Magliozzi, R., et al. 2006. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 65:124.
18. Reboldi, A., Coisne, C., Baumjohann, D., et al. 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10:514.
19. Melzer, N., Meuth, S. G. and Wiendl, H. 2009. CD8(+) T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J. 23:3659.
20. Goebels, N., Hofstetter, H., Schmidt, S., Brunner, C., Wekerle, H. and Hohlfeld, R. 2000. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123:508.
21. Wakefield, A. J., Sawyerr, A. M., Dhillon, A. P., et al. 1989. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 2:1057.
22. Baumgart, D. C. and Sandborn, W. J. 2012. Crohn's disease. Lancet 380:1590.
23. Giancotti, F. G. and Ruoslahti, E. 1999. Integrin signaling. Science (New York, NY) 285:1028.
24. Thomas, S. and Baumgart, D. C. 2012. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 20:1.
25. Campbell, J. J., Hedrick, J., Zlotnik, A., Siani, M. A., Thompson, D. A. and Butcher, E. C. 1998. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science (New York, NY) 279:381.
26. Engelhardt, B. and Ransohoff, R. M. 2012. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 33:579.
27. Sheremata, W., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J. and Koller, M. 1999. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52:1072.
28. Miller, D. H., Khan, O. A., Sheremata, W. A., et al. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15.
29. Polman, C. H., O'Connor, P. W., Havrdova, E., et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899.
30. Rudick, R. A., Stuart, W. H., Calabresi, P. A., et al. 2006. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354:911.
31. Kleinschmidt-DeMasters, B. K. and Tyler, K. L. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353:369.
32. Langer-Gould, A. and Steinman, L. 2006. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr. Neurol. Neurosci. Rep. 6:253.
33. Van Assche, G., Van Ranst, M., Sciot, R., et al. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353:362.
34. Astrom, K. E., Mancall, E. L. and Richardson, E. P. 1958. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81:93.
35. Simpson, D. M. 2011. HIV-associated PML: changing epidemiology and clinical approach. Cleve. Clin. J. Med. 78(Suppl 2):S24.
36. Major, E. O., Amemiya, K., Tornatore, C. S., Houff, S. A. and Berger, J. R. 1992. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin. Microbiol. Rev. 5:49.
37. Berger, J. R. and Houff, S. 2009. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann. Neurol. 65:367.
38. Khanna, N., Elzi, L., Mueller, N. J., et al. 2009. Incidence and outcome of progressive multifocal leukoencephalopathy over years of the Swiss HIV Cohort Study. Clin. Infect. Dis. 48:1459.
39. Cinque, P., Bossolasco, S., Brambilla, A. M., et al. 2003. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J. Neurovirol. 9(Suppl 1):73.
40. Chabwine, J. N., Lhermitte, B., Da Silva, M. O., Buss, G., Maeder, P. and Du Pasquier, R. A. 2012. Progressive multifocal leukoencephalopathy in a patient with transitory lymphopenia. Neurology 78:2000.
41. Chowdhary, S., Chalmers, L. M. and Chamberlain, M. 2007. Non-HIV-related progressive multifocal leukoencephalopathy (PML): a tertiary cancer center experience. J. Neuroimaging. 17:69.
42. Carson, K. R., Focosi, D., Major, E. O., et al. 2009. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10:816.
43. Dahlhaus, S., Hoepner, R., Chan, A., et al. 2013. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J. Neurol. Neurosurg. Psychiatry 72:402.
44. Khatri, B. O., Man, S., Giovannoni, G., et al. 2009. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72:402.
45. Fox, R. 2011. Advances in the management of PML: focus on natalizumab. Cleve. Clin. J. Med. 78(Suppl 2):S33.
46. Gray, F., Bazille, C., Adle-Biassette, H., Mikol, J., Moulignier, A. and Scaravilli, F. 2005. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J. Neurovirol. 11(Suppl 3):16.
47. Steiner, I. and Berger, J. R. 2012. Update on progressive multifocal leukoencephalopathy. Curr. Neurol. Neurosci. Rep. 12:680.
48. Bellizzi, A., Anzivino, E., Rodio, D. M., et al. 2013. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol. J. 10:298.
49. Koralnik, I. J., Du Pasquier, R. A. and Letvin, N. L. 2001. JC virusspecific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J. Virol. 75:3483.
50. Gorelik, L., Goelz, S. and Sandrock, A. W. 2009. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361:2487; author reply 2489-90.
51. Gorelik, L., Lerner, M., Bixler, S., et al. 2010. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 68:295.
52. Carruthers, R. L., Chitnis, T. and Healy, B. C. 2013. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy. Mult. Scler. 20:757.
53. Clifford, D. B., Nath, A., Cinque, P., et al. 2013. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J. Neurovirol 19:351.
54. Alstadhaug, K. B., Croughs, T., Henriksen, S., et al. 2014. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol 71:1030.
55. Giacomini, P. S., Rozenberg, A., Metz, I., Araujo, D., Arbour, N. and Bar-Or, A. 2014. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N. Engl. J. Med. 370:486.
56. O'Connor, P., Goodman, A., Kappos, L., et al. 2014. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 83:78.
57. Butzkueven, H., Kappos, L., Pellegrini, F., et al. 2014. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J. Neurol. Neurosurg. Psychiatry. 85:1190.
58. Lee, P., Plavina, T., Castro, A., et al. 2013. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J. Clin. Virol. 57:141.
59. Cutter, G. R. and Stüve, O. 2014. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult. Scler. 20:1304.
60. Lonergan, R., Kinsella, K., Kelly, S., et al. 2013. Does jcv antibody positivity encourage cessation of natalizumab therapy in multiple sclerosis? J. Neurol. Neurosur. Ps. 84:e2.
61. Plavina, T., Subramanyam, M., Bloomgren, G., et al. 2013. JCV antibody index stratifies PML risk in natalizumab-treated MS patients. The CMSC meeting
62. Schwab, N., Schneider-Hohendorf, T., Posevitz, V., et al. 2013. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81:865.
63. Schneider-Hohendorf, T., Philipp, K., Husstedt, I. W., Wiendl, H. and Schwab, N. 2014. Specific loss of cellular L-selectin on CD4+ T cells is associated with PML development during HIV infection. AIDS (London, England)
64. Kitley, J., Evangelou, N., Kuker, W., Jacob, A., Leite, M. I. and Palace, J. 2014. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J. Neurol. Sci. 339:223.
65. Lee, D.-H., Laemmer, A. B., Waschbisch, A., et al. 2014. Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report. J. Med. Case Rep. 8:155.
66. Romme Christensen, J., Ratzer, R., Bornsen, L., et al. 2014. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 82:1499.
67. Rothhammer, V., Heink, S., Petermann, F., et al. 2011. Th17 lymphocytes traffic to the central nervous system independently of {alpha}4 integrin expression during EAE. J. Exp. Med. 208:2465.
68. Rothhammer, V., Muschaweckh, A., Gasteiger, G., et al. 2014. α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathol. Commun. 2:27.
69. Flanagan, K., Fitzgerald, K., Baker, J., et al. 2012. Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS ONE 7:e40443.
70. Larochelle, C., Cayrol, R., Kebir, H., et al. 2012. Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. Brain 135:2906.
71. Schneider-Hohendorf, T., Rossaint, J., Mohan, H., et al. 2014. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J. Exp. Med. 211:1833.
72. Stüve, O., Marra, C. M., Bar-Or, A., et al. 2006. Altered CD4+/ CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 63:1383.
73. Bittner, S., Simon, O. J., Gobel, K., Bien, C. G., Meuth, S. G. and Wiendl, H. 2013. Rasmussen encephalitis treated with natalizumab. Neurology 81:395.
74. Vinhas de Souza, M., Keller-Stanislawski, B., Blake, K., Hidalgo-Simon, A., Arlett, P. and Dal Pan, G. 2012. Drug-induced PML: a global agenda for a global challenge. Clin. Pharmacol. Ther. 91:747.
75. Wiendl, H. 2012. Neuroinflammation: the world is not enough. Curr. Opin. Neurol. 25:302.